The longevity market map: why the mid-priced tier is still missing

The most profitable end of preventive health and the most effective end are not the same place. That distance is the whole argument.

Money in this category collects where it is easiest to charge, which is not where the health is. At one end sit annual memberships, hotel wings, imaging suites and the promise of outsmarting ageing, bought by a very small and very wealthy group. At the other sit rings, patches, finger-prick kits and downloadable protocols, bought by almost everyone. What decides who dies early lies between the two, and it is dull: blood pressure, lipids, glucose, a handful of cancers, muscle, sleep, mental health. Nobody designed that mismatch. It is what happens when the thing that sells easily and the thing that works are different objects, and nothing in the incentives closes the gap.

This is an educational and strategic perspective, not personal medical advice. The views are the author's own and not statements by Atlas Cove Lda.

Four layers, and what each one leaves undone

Take the marketing language off the offers and the category resolves into four recognisable groups. They fail the same customer in four different ways, and those failures are the map.

Heritage retreats sell a ritual

Sanatoriums with a century behind them that learned to use Instagram. Lakes, mountains, thermal baths, usually attached to a five-star hotel. You buy a programme of one or two weeks: fasting or controlled eating, blood work, basic imaging, fitness testing, breath work, massage, spa time, sometimes something light and cognitive. With travel and upgrades counted, the price runs into five figures for the week.

Two things are done extremely well. The hospitality is choreographed to the minute, and the story is excellent: I go every year, I reset, I stay young. What the model does not contain is risk management that runs all year, because it was never designed to. You arrive, you leave, and nothing in the structure carries responsibility for the eleven months in between.

Membership clinics sell information and a signal

The addresses are predictable: New York, London, Zurich, Dubai, Singapore. Memberships start around ten thousand euros a year and reach a quarter of a million dollars, marketed openly as status alongside the most advanced testing money can buy. The data haul is enormous: whole-body MRI or CT, cardiac imaging, genome and exome sequencing, polygenic scores, very large blood panels, microbiome, VO2max, biological age tests, wearables.

Members buy three things: information, access to one or two physicians whose names they recognise, and the signal that they have a longevity team. All three are legitimate purchases. Expensive locations, thick staffing and tiny client lists are not inefficiencies bolted onto the model. They are the model. Nobody optimises a two hundred thousand dollar membership down to a price an engineer would pay, because the cost base fights you and the story fights you harder. More on whether anything in this category scales at all.

Hybrid centres sell breadth

Almost every large city has a version. Executive check-ups built on labs, ECG and ultrasound, sometimes CT or MRI. Sports performance work, hormone optimisation, IVs, aesthetics, nutrition, general psychology. A subscription layered over fee for service. Serious internists and cardiologists run some of these places, carefully. Others are gyms with an account at a laboratory.

Longevity here is mostly a word applied to conventional check-ups, sports medicine and upsells. They are broad and rarely deep. The buyer's real difficulty is that one label covers both versions, and at the point of purchase there is no reliable way to tell which one you are in.

Consumer tools sell awareness

The outer ring is now enormous: sleep and HRV trackers, continuous glucose monitors, rings, bands, watches, finger-prick panels posted to your house, supplement subscriptions, and a content economy of protocols, podcasts and self-experiment playbooks.

This layer is genuinely good at awareness. Integration is where it fails. You end up with more readings than anyone can act on and no clinical plan behind them, because no one along that chain carries structural responsibility for you across a decade. Four layers, one hole.

The levers that decide who dies early are dull

Read as an engineer and an allocator rather than as a mystic, the picture barely moves from year to year.

Across Europe, cancer and cardiovascular disease are still what kills people before their time. Depending which dataset you take, they account together for about two thirds of the early deaths that non-communicable disease causes. The largest avoidable losses inside that sit in five places: what people eat, smoking, glucose, lipids, blood pressure. Socioeconomic position still predicts who dies early, with lower-income groups carrying more cardiovascular and cancer burden and getting fewer healthy years out of a life. Ultra-processed food shows a measurable association with dying early: every ten percent higher share of it in the diet correlates with a few percent higher risk of death before 75.

Which leaves a short list of levers with strong evidence behind them.

Cardiometabolic risk: smoking, blood pressure, ApoB and LDL, HbA1c, visceral adiposity.
Selected cancers: colorectal, breast, cervical, and lung in high-risk groups, depending on age and history.
Physical function: grip strength, gait speed, muscle mass, VO2max.
Sleep and mental health: depression, anxiety and sleep disorders, all of which feed indirectly into both cancer and cardiovascular disease.

Everything under that sits in weaker tiers. Emerging human data covers biological age clocks derived from DNA methylation or blood biomarkers, structured resistance training for older adults, and particular dietary patterns. Below it comes mechanistic and animal work: cellular senescence, autophagy interventions, plasma exchange, and a long catalogue of molecules sold on the word longevity. Below that again is speculation, meaning off-label drug stacks and devices marketed as anti-ageing.

The mismatch is plain. The strongest levers are boring and they scale beautifully. The theatrical products are the visible ones, aimed at people who already outlive everyone else. That is an ethical problem. It is also a margin and scale problem, and it sits close to what the longevity industry prefers not to say out loud.

What the expensive end has already proved

I don't worship the high-end clinics and I don't underestimate them either. Read as prototypes rather than as finished products, they have established four things.

Willingness to pay is no longer a hypothesis. Thousands of people happily spend between eight thousand and two hundred and fifty thousand dollars a year on intensive diagnostics, repeat scans and bespoke prevention. That is a demand signal, and it is the most useful thing the top of the market has produced.
Prevention was made aspirational. Architecture, concierge service and exclusivity are levers on behaviour, and they work. They get people through a full day of assessment that those same people would otherwise postpone indefinitely.
Workflow gets tested in the open. How many diagnostic stations fit into an eight-hour day before quality slips. What the real no-show rate is for an annual scan when clients fly in for it. How many hours of physician time a genuinely complex client consumes across twelve months. That learning is real intellectual property, even where the science around it is messy.
Biomarkers and protocols get a testbed. The roundtables on longevity clinics, and work such as Mironov et al., have begun to codify which biomarkers are in use, how often they are taken, and what ranges are being claimed for them.

Treat the top of the market as a research and operations laboratory and it becomes easier to reason about.

The ceiling that efficiency cannot remove

The unit economics are the product

Expensive real estate, a hotel-grade fit-out, nurses on hand for VIPs, concierge cover around the clock, small client panels. None of that is a bug to be engineered away. It is what the customer came for. You cannot spreadsheet your way from a hundred thousand euro membership down to a five thousand euro one, because the thing that breaks in the process is exclusivity, and exclusivity is the actual product.

Evidence discipline is thin

The field has no standardised, validated biomarker set for biological age and no harmonised protocol defining what a longevity assessment even consists of. That doesn't make it pseudoscience. It means a great deal of it is experimental and is being sold as established.

Whole-body MRI is the clean example. Interest is growing, amplified by influencers and by clinics, and it does pick up serious disease early in groups already at higher risk. Professional bodies including the American College of Radiology also say the evidence isn't sufficient to recommend scanning the whole body in people who have no symptoms and no elevated risk, because of overdiagnosis and everything the follow-up testing sets in motion. Running ahead of the evidence curve is reasonable for a research operation. It turns dangerous the moment it gets painted as precision medicine.

The data sits in silos

A single clinic in the Bay Area gathers over 150GB per client across imaging, genomics, labs and wearables, and charges between eight and nineteen thousand dollars a year for it. That data is held as an internal asset rather than structured into open cohorts that would move the field forward.

The reputation risk is collective

When a quarter-million-euro membership bundles solid cardiovascular prevention together with speculative interventions and vague promises, critics do not do anyone the courtesy of separating the two. They go after the category, and the careful operators inside it pay for that too.

What it looks like if you build it like infrastructure

The question that forces discipline on me is simple. What would this be if we built it like infrastructure instead of like a private club?

Infrastructure has properties you can check for. Scope is tightly defined. Components are standardised. Interfaces with public systems are explicit. The whole thing is designed for volume and repetition rather than for a signature experience. In preventive health that means five things.

A narrow scope with a controlled frontier

Anchor on cardiometabolic risk, the cancer screening that is genuinely high yield for that person, strength and function and falls risk, and sleep and mental health. Above that, permit a frontier: advanced imaging, genomics, biological age scores, novel biomarkers. Permit it on one condition, which is that the result either changes what happens next or the thing is being studied under protocol, with consent naming it as experimental. Nothing goes in because a competitor put it in.

Diagnostics as a utility rather than a display

Instead of trophy panels: a standard baseline adjusted for age and sex, escalation triggered by risk models, by early findings and by family history, and integration between lab and software tight enough that cost per datapoint falls as volume rises. The value was never in the length of the report. The value is the ratio of signal to noise, and whether anyone acts on it.

The clinic as an operating system, not a hotel

The operating system underneath is the scarce asset, rather than a star physician or a view over the marina. Physicians take the decisions that need a physician and handle complexity. Nurses and allied health staff run standard protocols and follow-ups. Coaches and behaviour specialists own adherence. All of it sits on versioned pathways that get updated when the evidence moves.

A mundane detail makes the case better than the theory does. In plenty of EU clinics today, someone signs three separate paper consent forms, one for bloods, one for imaging, one for data sharing, because the safety checklist for the scanner exists only as a locked PDF coming out of an ageing LaserJet in the corner of an office. Staff then key the same details into two systems that do not talk to each other. That friction is where infrastructure thinking has to start.

Geography as a lever on cost and on behaviour

The location question has nothing to do with which place photographs best. Three practical tests decide it. Is the regulation serious, and aligned with EU-level safety standards. Do property and labour cost structurally less than they do in a wealth hub. Does the surrounding environment make behaviour change easier, which means walkability, food culture, climate and pace of life. Portugal is interesting on all three today, though the specifics depend entirely on the law as it stands and belong with qualified EU and Portuguese legal and tax counsel rather than with me.

A price that can be paid again next year

Neither mass market nor yacht level. The band that matters is the one an engineer, a founder, a senior operator or a business owner can reach and then repeat annually without it becoming the expense that defines their year. Repeatability is the whole distinction. If your customer list turns out to be the same families already flying to the top tier, the middle layer isn't what you have built. You have built another top-tier brand with different furniture.

Three tiers, and the one nobody has built

Tier 1, luxury and research. Retreats, concierge memberships, research-minded clinics. High price, low volume, a lot of experimentation.
Tier 3, the public and insured system. Hospitals, primary care, statutory screening. Indispensable, overloaded, politically constrained, with prevention budgets that are thin and short term.
Tier 2, prevention built as infrastructure. Evidence-heavy risk management, run as a system rather than as a programme, priced for a broad band of working professionals. This is the white space.

Today: a great many top-tier cathedrals, a loud consumer layer underneath, public systems short of resources trying to plug holes, and no coherent middle capacity worth the name.

Why the middle stays empty

Three reasons, and none of them is that nobody thought of it. The luxury incumbents are brand-trapped: standardise, automate, price for the middle, and the exclusivity they sell dilutes itself. Public systems cannot move at that speed either, because they answer to political cycles and budget ceilings rather than to a return on prevention that lands in ten years under somebody else's name. And consumer health companies stop deliberately where the clinical weight begins. Data, coaching, content, and no further, because the liability and regulatory footprint of actually running a clinic is a different business and they know it.

Each of those is a sensible position for the company holding it. Together they leave the most useful layer unbuilt.

The four risks that would sink it

Whenever this starts to feel straightforward, I reread the list below.

Over-testing and cascades

A full day of diagnostics invites incidental findings and false positives by design. The radiology community is openly arguing about the perils and the promise of scanning the whole body, and the specific worry is downstream anxiety and unnecessary procedures in people who were at low risk when they walked in. Over-testing harms individual clients, destroys trust with the physicians who refer, and consumes your own capacity with follow-up that never needed to happen. A middle-tier operator has to write down what it will refuse to do, not only what it offers.

Evidence drift

The pull toward adding another biomarker and another intervention never stops. Mironov and colleagues have sketched a way of sorting biomarkers and interventions by how strong the evidence behind each one is, and which of them belong in a healthy longevity clinic at all. Standardisation is still weak, and the roundtable reports themselves flag the heterogeneity and the confusion around biological age scores and what counts as a longevity biomarker.

My own rule would run to three lines. Strong human outcome data goes into the core offering. Mechanistic or early human data goes into a clearly labelled optional frontier. Animal and in-vitro work stays in trials and never reaches the brochure. If an operator cannot show you that hierarchy in writing, it is running on vibes.

Adherence, which is where the economics live

Selling one big day in the scanner and the laboratory is easy. Holding someone to their medication, their strength work, their sleep and their food for the next three to five years is hard. Without adherence the clinical outcomes disappoint, lifetime value falls, and the cost of acquiring the client stops being justifiable. A middle-tier model without a serious behaviour system is an expensive on-ramp that leads nowhere. It is the same problem as the retention question sitting underneath all of this, seen from the operator's side of the desk.

Data and governance

Frequent labs, imaging, wearables and AI risk scores raise governance questions that need answering before the data exists. Who owns the raw data, and who owns the models built on top of it. How it gets de-identified before it is used for learning. What happens when an employer or an insurer asks for access. Brussels is already drafting cardiovascular and cancer prevention plans, plus wider data initiatives on non-communicable disease, and the regulatory climate will only tighten. An operator treating governance as an afterthought is carrying a liability it has not priced.

Why this is possible now

On the demand side

Life expectancy gains across Europe have stalled, and in several countries they have reversed, with rising obesity, poor diet and inactivity driving that through cancer and cardiovascular disease. Policymakers have started saying so bluntly, naming those two as the dominant causes of early death. EU-level cardiovascular health plans are now being drafted to sit beside Europe's Beating Cancer Plan. Meanwhile a large group of health-literate professionals wants more than a basic check-up and does not see itself in a hundred thousand euro concierge membership.

On the supply side

The segment is already worth billions and is on a path to multiply by 2035, and most of the capital so far has gone into top-tier brands and consumer devices. Cathedrals have been built. Dashboards have been built. The plumbing is what is missing, meaning the connection between prevention that works and ordinary professionals carrying serious responsibility, at a sensible price. Proven willingness to pay, life expectancy that has stopped improving, political pressure on non-communicable disease, and infrastructure nobody has laid yet: that combination is what makes a middle tier possible rather than merely desirable.

Three questions worth asking any operator

If you are evaluating anything in this category, ask three blunt questions and ignore the photography.

Which parts of this are standardised?

If the answer is that everything is bespoke, what you are buying is a craft studio rather than infrastructure. Ask to see versioned care pathways, clear inclusion and exclusion criteria for each diagnostic, and a written evidence hierarchy covering every intervention on offer.

What does the business learn from each client, and who ends up owning it?

If the data model turns out to be a graveyard of PDFs and private dashboards, the learning loop is storytelling. What you want is structured, queryable data across cohorts, consent pathways defined clearly enough to allow secondary use, and a plan to publish something, or at minimum internal evidence that would survive somebody hostile reading it.

In ten years, is this a brand or is it infrastructure?

Both make money. A brand can exit cleanly and leave very little behind it. Infrastructure alters how a whole population ages, and once it is in place it is hard to dislodge. My working assumption, and the argument I keep having with myself at three in the morning, is that the leverage will sit with the teams quietly laying middle-tier pipes while everyone else polishes lobbies.

Done properly, this stops being a luxury identity and turns into an unremarkable utility, something serious professionals put in the annual budget beside tax advice and cloud hosting. So the strategic question stays simple. Cathedrals, gadgets, or the plumbing that decides who gets the extra healthy years?

Where this argument is judgement rather than evidence

Parts of this carry different weights, so I would rather mark the soft joints myself.

The empty middle is an inference. It rests on the operators I can see and the ones I cannot name, which is the weakest form of evidence there is. No published dataset shows the size of a mid-priced structured prevention market in Europe. Something functional may well be getting assembled quietly inside insurers or occupational health providers, where I would not see it.

The mortality figures are population statistics. They tell you what a health system could achieve across millions of people. They say nothing about what a single operator with a few dozen clients a year changes. The two thirds figure also moves with the dataset, which is why I gave it as an approximation.

The Portugal case is time-limited and legally contingent. Regulation, labour costs and tax treatment all change, and nothing I have said about location survives without current advice from people qualified to give it.

And the commercial thesis is mine. That a middle tier can be built profitably is a judgement about the constraints the incumbents are under, not a finding. People who have built in this space disagree with me, and the strongest argument against my own would be a top-tier operator moving downmarket without losing the customer it already has.

Questions readers ask about this

What is the middle tier, concretely?

Evidence-heavy prevention and risk management run as a system rather than as a programme, with a narrow clinical scope, diagnostics used as a utility, and a price a senior professional can pay more than once. Repeatability is the distinguishing feature. If it only works once in a decade, it is something else wearing the label.

Are the expensive membership clinics a waste of money?

No, though what they are worth depends on what you are buying them for. They proved willingness to pay, made prevention aspirational, and generated genuine operational learning. What they cannot do is scale, because the cost structure they would have to shed is the thing being sold.

Should someone with no symptoms buy a whole-body scan?

Professional bodies including the American College of Radiology say there is not enough evidence to recommend it for people who are symptom-free and at average risk, because of overdiagnosis and the testing that follows a finding. Higher-risk groups are a different situation, and that is a conversation for a doctor who knows your history rather than for an article.

What should an investor look at first?

What is being standardised, what the business learns from each client and who owns that learning, and whether the thing will look like a brand or like infrastructure in ten years. The wider question of how health businesses actually make their money sits underneath all three.

This is an educational and strategic perspective, not personal medical advice. The views are the author's own and not statements by Atlas Cove Lda.

Apply to a cohort

Lisa Wuerden · Co-Founder

Co-founder, brand and product